Pharmacogenetics of hepatitis C

Recent discoveries have highlighted the influence of host genomics on hepatitis C virus (HCV) infection outcomes. As a result, our views on hepatitis C pathogenesis and therapeutic approaches have been transformed. The recognition of the impact of single-nucleotide polymorphisms (SNPs) of the genes...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2012-03, Vol.67 (3), p.523-529
Main Authors: Soriano, Vincent, Poveda, Eva, Vispo, Eugenia, Labarga, Pablo, Rallón, Norma, Barreiro, Pablo
Format: Article
Language:English
Subjects:
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral Agents - administration & dosage
Biological and medical sciences
Clinical outcomes
Drug-Related Side Effects and Adverse Reactions - genetics
Genetics
Genomics
Hepatitis
Hepatitis C
Hepatitis C - drug therapy
Hepatitis C - immunology
Hepatitis C virus
Human immunodeficiency virus
Human viral diseases
Humans
Infectious diseases
Medical sciences
Pathogenesis
Pharmacogenetics
Pharmacology
Pharmacology. Drug treatments
Polymorphism
Treatment Outcome
Viral diseases
Viral hepatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent discoveries have highlighted the influence of host genomics on hepatitis C virus (HCV) infection outcomes. As a result, our views on hepatitis C pathogenesis and therapeutic approaches have been transformed. The recognition of the impact of single-nucleotide polymorphisms (SNPs) of the genes interleukin 28B (IL28B), inosine triphosphatase (ITPA) and low-density lipoprotein cholesterol receptor (LDLR) may lead to refinements in the pharmacogenomic prediction of antiviral response and drug-related toxicities and favour the discovery of new therapeutic targets for hepatitis C. Although the relevance of host genetics may be less in the setting of very potent new direct-acting antivirals (DAAs), genetic markers may continue to aid decision making regarding the length of therapy. Moreover, in several populations, such as HIV/HCV-coinfected patients, current therapy with peginterferon-α/ribavirin will continue in use for most patients, and thus host factors will retain their predictive value for treatment outcomes for a while.
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkr506